Virax Biolabs Group Limited VRAX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -86.01%
- 1 year
- -91.84%
- Open
- 1.29
- Prev close
- 1.32
- Mkt cap
- 1.63M
- Vol
- 23.67K
- Avg vol
- 391.49K
- EPS
- -12.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.18
- High
- 1.29
- Forward P/E
- -1.01
- Beta
- 1.93
- Short ratio
- 0.11
- Inst. own
- 5.37%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.92
- 200-d avg
- 1.66
- 1y target
- 0.00
Key statistics
- Market cap
- 8.34M
- Enterprise value
- 1.17M
- Trailing P/E
- 0.00
- Forward P/E
- -1.01
- PEG ratio
- 0.00
- Price / sales
- 53.30
- Price / book
- 0.92
- EPS (TTM)
- -2.61
- Beta
- 1.93
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 156.42K
- Revenue growth
- 2752.20%
- Free cash flow
- -4.99M
- Total cash
- 3.67M
- Total debt
- 224.30K
- Return on equity
- -95.98%
- Shares outstanding
- 4.34M
- Short % of float
- 11.01%
- 50-day average
- 1.92
- 200-day average
- 1.66
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Virax Biolabs Group Limited
Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- viraxbiolabs.com
News
- Virax Biolabs Enter Agreements With Three Chinese Distributors For Its ImmuneSelect Research-Use Immune Profiling Products
- Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Large Decline in Short Interest
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Virax Biolabs Management Believes Current Valuation Doesn't Fully Reflect Its Audited Financial Position, Clinical And Development Programs, Commercial Progress Or Strategic Assets
Your note
Sign in to keep a note on VRAX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 4.50% | 145,400 | 279.17K | Sep 29, 2024 |
| Squarepoint Ops LLC | 1.26% | 40,620 | 77.99K | Sep 29, 2024 |
| UBS Group AG | 0.64% | 20,530 | 39.42K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.36% | 11,635 | 22.34K | Sep 29, 2024 |
| Headlands Technologies LLC | 0.01% | 185 | 355 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.02% | 542 | 1.04K | Oct 30, 2024 |